Longitudinal change of biomarkers in cognitive decline.

OBJECTIVE To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD). DESIGN Cohort study. SETTING The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative. PARTICIPANTS A total of 819 participants 55 to 90 years of age with normal cognition, mild cognitive impairment, and AD who were followed up during the period from 2005 to 2007. MAIN OUTCOME MEASURES Rates of change in level of Aβ42 in CSF, FDG uptake, hippocampal volume, and the Alzheimer Disease's Assessment Scale-cognitive subscale score during up to 36 months of follow-up by diagnostic group as well as prediction of cognitive change by each biomarker. RESULTS Reductions in the level of Aβ42 in CSF were numerically greater in participants with normal cognition than in participants with mild cognitive impairment or AD; whereas both glucose metabolic decline and hippocampal atrophy were significantly slower in participants with normal cognition than in participants with mild cognitive impairment or AD. Positive APOE4 status accelerated hippocampal atrophic changes in participants with mild cognitive impairment or AD, but did not modify rates of change in level of Aβ42 in CSF or FDG uptake. The Alzheimer Disease's Assessment Scale-cognitive subscale scores were related only to the baseline level of Aβ42 in CSF and the baseline FDG uptake in participants with normal cognition, which were about equally associated with change in FDG uptake and hippocampal volume in participants with mild cognitive impairment and best modeled by change in FDG uptake in participants with AD. CONCLUSION Trajectories of Aβ42 level in CSF, FDG uptake, and hippocampal volume vary across different cognitive stages. The longitudinal patterns support a hypothetical sequence of AD pathology in which amyloid deposition is an early event before hypometabolism or hippocampal atrophy, suggesting that biomarker prediction for cognitive change is stage dependent.

[1]  K. Blennow,et al.  CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study , 2003, Neurology.

[2]  N. Schuff,et al.  Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study , 2010, Neurobiology of Aging.

[3]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Jack,et al.  MRI correlates of neurofibrillary tangle pathology at autopsy , 2008, Neurology.

[5]  Danielle J. Harvey,et al.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes , 2010, Alzheimer's & Dementia.

[6]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[7]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[8]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. , 2000, Neuroscience letters.

[9]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[10]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[11]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[12]  K. Blennow,et al.  Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. , 2010, Archives of neurology.

[13]  S. Santi,et al.  Hippocampal hypometabolism predicts cognitive decline from normal aging , 2008, Neurobiology of Aging.

[14]  G. Alexander,et al.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. , 2002, The American journal of psychiatry.

[15]  Rachel L. Mistur,et al.  FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[17]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[18]  K Kontula,et al.  Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. , 1995, The New England journal of medicine.

[19]  Brigitte Landeau,et al.  Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: A longitudinal MRI study , 2005, NeuroImage.

[20]  K. Blennow,et al.  Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. , 2007, Journal of Alzheimer's disease : JAD.

[21]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[22]  Cindee M. Madison,et al.  Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.

[23]  K. Blennow,et al.  Longitudinal stability of CSF biomarkers in Alzheimer's disease , 2007, Neuroscience Letters.

[24]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[25]  A. Drzezga,et al.  Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[27]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[28]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[29]  C. Jack,et al.  Atrophy rates accelerate in amnestic mild cognitive impairment , 2008, Neurology.

[30]  G. B. Frisoni,et al.  The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort , 2010, Neurobiology of Aging.

[31]  E. Duchesnay,et al.  Longitudinal brain metabolic changes from amnestic Mild Cognitive Impairment to Alzheimer's disease , 2009, NeuroImage.

[32]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[33]  Leslie M. Shaw,et al.  PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative , 2007, Neurosignals.

[34]  Trey Sunderland,et al.  Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.

[35]  G. Schellenberg,et al.  Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. , 2009, Archives of neurology.

[36]  Henrik Zetterberg,et al.  Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease , 2009, PloS one.

[37]  N. Jewell,et al.  To GEE or Not to GEE: Comparing Population Average and Mixed Models for Estimating the Associations Between Neighborhood Risk Factors and Health , 2010, Epidemiology.

[38]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[39]  S. Resnick,et al.  Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype , 2000, Neurology.

[40]  N. Schuff,et al.  Longitudinal volumetric MRI change and rate of cognitive decline , 2005, Neurology.

[41]  Frederik Barkhof,et al.  Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study , 2010, Neurobiology of Aging.